---
title: "Integrating untargeted metabolomics, genetically informed causal inference, and pathway enrichment to define the obesity metabolome"
description: |
  * **Approach**: A multi-omics framework was developed, combining **untargeted metabolomics** (measuring both known and unknown metabolites) with **two-sample Mendelian Randomization (MR)** using metabolite-QTLs (mQTLs).
  * **Causal Findings**: **23 metabolites** (15 known and 8 unknown) were identified as causally associated with BMI, with specific pathways like **amino acid catabolism** and **lipid metabolism** being implicated in the obesity metabolome.
  * **Innovation**: A novel **pathway enrichment method** was used to infer the metabolic function of the causally associated **unknown metabolites** based on their shared genetic links with identified metabolites.
date: last-modified
categories: [bioinformatics, causal inference, mendelian randomization, metabolomics, multi-omics]
---

**PubMed:** [32467615](https://pubmed.ncbi.nlm.nih.gov/32467615/)
**DOI:** [10.1038/s41366-020-0603-x](https://doi.org/10.1038/s41366-020-0603-x)
**Overview generated by:** Gemini 2.5 Flash, 27/11/2025

## Background and Objective

**Obesity** is associated with significant metabolic disruption. Understanding the **causal connections** between obesity and changes in metabolite levels is crucial for identifying new intervention targets. Previous studies using **Mendelian Randomization (MR)** to infer causality between metabolites and obesity often ignored the majority of data generated by **untargeted metabolomics**—specifically, the signals from **unknown or unidentified metabolites**.

This study aimed to develop a comprehensive framework that integrates **untargeted metabolomics**, **genetics**, and **pathway enrichment analysis** to:
1.  Identify a broad spectrum of metabolites causally related to Body Mass Index (**BMI**).
2.  Characterize the biological **pathways** involved in the **obesity metabolome**, including those represented by unidentified metabolites.

## Study Methods

The authors utilized a multi-stage approach across three large cohorts:

1.  **Metabolomic Profiling:** Untargeted metabolomic profiling was conducted on samples from the **Framingham Heart Study (FHS)**, generating quantitative signals for both known (identified) and unknown (unidentified) metabolites.
2.  **Genome-Wide Association Study (GWAS):** A GWAS was performed to identify **metabolite-QTLs (mQTLs)**—genetic variants associated with the levels of both known and unknown metabolites. These mQTLs served as the **instrumental variables (IVs)** for the subsequent MR analysis.
3.  **Two-Sample Mendelian Randomization (MR):**
    * The mQTLs identified from the FHS metabolomics GWAS were used as IVs.
    * The exposure was each metabolite (known and unknown).
    * The outcome was **BMI**, using summary statistics from a large published BMI GWAS.
    * **Multivariable MR** was applied to test for independence among groups of putatively co-regulated metabolites.
4.  **Pathway Enrichment Analysis:** To interpret the role of the unknown metabolites, a novel **Pathway Enrichment Analysis** method was developed. This method uses the **shared genetic architecture** (i.e., common mQTLs) between unknown and known metabolites to infer the metabolic pathway of the unknown metabolites.

## Key Results and Findings

### Causal Metabolites
* The study identified **23 metabolites** (15 known and 8 unknown) that were **causally associated** with BMI.
* **Pro-Obesity Metabolites:** Metabolites whose higher levels were causally linked to **higher BMI** included certain **amino acid catabolites**, **medium-chain acylcarnitines**, and metabolites related to the **carnitine cycle** and **fatty acid oxidation**.
* **Anti-Obesity Metabolites:** Metabolites whose higher levels were causally linked to **lower BMI** included **glycine**, **acetylated/formylated amino acids**, and several **glycerophospholipids**.

### Defining the Obesity Metabolome
The integrated analysis defined the **obesity metabolome** as being characterized by a metabolic shift involving:
1.  **Impaired Amino Acid Catabolism:** Specifically, branched-chain amino acid (BCAA) and aromatic amino acid catabolites showed a strong causal link with higher BMI.
2.  **Dysfunctional Lipid Metabolism:** The enrichment analysis linked BMI to pathways of lipid metabolism, particularly those involving **glycerophospholipids** and the **carnitine shuttle**.

### Importance of Unknown Metabolites
The inclusion of **8 causally-associated unknown metabolites** expanded the definition of the obesity metabolome. The novel pathway enrichment approach successfully mapped these unknown metabolites to relevant metabolic pathways (e.g., lipid and amino acid metabolism) based on their shared genetic control with known metabolites.

## Conclusions and Significance

The comprehensive framework successfully leveraged the power of **untargeted metabolomics** in combination with **genetically informed causal inference (MR)** and a novel **pathway enrichment tool**. This approach provides a more complete, systems-level view of the metabolic disturbances associated with obesity.

The identified causal metabolites and pathways offer promising avenues for targeted therapeutic and diagnostic interventions aimed at treating obesity and its related metabolic diseases.